The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells

被引：7
|
作者：
Na, Yu Ran [1 ]
Kim, Jin Young [2 ]
Song, Chang Ho [1 ]
Kim, Mikyung [3 ]
Do, Yen Thi [1 ]
Vo, Tam Thuy Lu [3 ]
Choi, Eunsom [1 ]
Ha, Eunyoung [3 ]
Seo, Ji Hae [3 ]
Shin, So-Jin [1 ]
机构：
[1] Keimyung Univ, Sch Med, Dept Gynecol & Obstet, Daegu 42601, South Korea
[2] Keimyung Univ Sch Med, Dept Internal Med, Daegu 42601, South Korea
[3] Keimyung Univ Sch Med, Dept Biochem, Daegu 42601, South Korea
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2021年 / 22卷 / 19期
基金：
新加坡国家研究基金会;
关键词：
AZD4547; cancer stem cells; fibroblast growth factor; fibroblast growth factor receptor; ovarian cancer; FACTOR RECEPTOR FAMILY; ADVANCED SOLID TUMORS; LUNG-CANCER; SELECTIVE INHIBITOR; POTENT; AMPLIFICATION; CHEMOTHERAPY; MECHANISMS; DISCOVERY; SAFETY;
D O I：
10.3390/ijms221910817
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The dysregulation of fibroblast growth factor (FGF) signaling has been implicated in tumorigenesis, tumor progression, angiogenesis, and chemoresistance. The small-molecule AZD4547 is a potent inhibitor of FGF receptors. This study was performed to investigate the antitumor effects and determine the mechanistic details of AZD4547 in ovarian cancer cells. AZD4547 markedly inhibited the proliferation and increased the apoptosis of ovarian cancer cells. AZD4547 also suppressed the migration and invasion of ovarian cancer cells under nontoxic conditions. Furthermore, it attenuated the formation of spheroids and the self-renewal capacities of ovarian cancer stem cells and exerted an antiangiogenic effect. It also suppressed in vivo tumor growth in mice. Collectively, this study demonstrated the antitumor effect of AZD4547 in ovarian cancer cells and suggests that it is a promising agent for ovarian cancer therapy.
引用
收藏
页数：15
相关论文
共 50 条
  • [1] FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
    Xie, Liang
    Su, Xinying
    Zhang, Lin
    Yin, Xiaolu
    Tang, Lili
    Zhang, Xiuhua
    Xu, Yanping
    Gao, Zeren
    Liu, Kunji
    Zhou, Minhua
    Gao, Beirong
    Shen, Danping
    Zhang, Lianhai
    Ji, Jiafu
    Gavine, Paul R.
    Zhang, Jingchuan
    Kilgour, Elaine
    Zhang, Xiaolin
    Ji, Qunsheng
    CLINICAL CANCER RESEARCH, 2013, 19 (09) : 2572 - 2583
  • [2] Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
    Coombes, R. C.
    Badman, P. D.
    Lozano-Kuehne, J. P.
    Liu, X.
    Macpherson, I. R.
    Zubairi, I
    Baird, R. D.
    Rosenfeld, N.
    Garcia-Corbacho, J.
    Cresti, N.
    Plummer, R.
    Armstrong, A.
    Allerton, R.
    Landers, D.
    Nicholas, H.
    McLellan, L.
    Lim, A.
    Mouliere, F.
    Pardo, O. E.
    Seckl, M. J.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [3] Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547
    Kas, Sjors M.
    de Ruiter, Julian R.
    Schipper, Koen
    Schut, Eva
    Bombardelli, Lorenzo
    Wientjens, Ellen
    Drenth, Anne Paulien
    de Korte-Grimmerink, Renske
    Mahakena, Sunny
    Phillips, Christopher
    Smith, Paul D.
    Klarenbeek, Sjoerd
    van de Wetering, Koen
    Berns, Anton
    Wessels, Lodewyk F. A.
    Jonkers, Jos
    CANCER RESEARCH, 2018, 78 (19) : 5668 - 5679
  • [4] Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
    Delpuech, Oona
    Rooney, Claire
    Mooney, Lorraine
    Baker, Dawn
    Shaw, Robert
    Dymond, Michael
    Wang, Dennis
    Zhang, Pei
    Cross, Sarah
    Veldman-Jones, Margaret
    Wilson, Joanne
    Davies, Barry R.
    Dry, Jonathan R.
    Kilgour, Elaine
    Smith, Paul D.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (11) : 2802 - 2813
  • [5] Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models
    Phanhthilath, Nikki
    Hakim, Sara
    Su, Catherine
    Liu, Andrea
    Subramonian, Divya
    Lesperance, Jacqueline
    Zage, Peter E.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1677 - 1686
  • [6] FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice
    Zhao, Qingxia
    Parris, Amanda B.
    Howard, Erin W.
    Zhao, Ming
    Ma, Zhikun
    Guo, Zhiying
    Xing, Ying
    Yang, Xiaohe
    SCIENTIFIC REPORTS, 2017, 7
  • [7] FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial-mesenchymal transition to gefitinib
    Luo, Hong
    Quan, Jin
    Xiao, He
    Luo, Jia
    Zhang, Qin
    Pi, Guocheng
    Ye, Yunfei
    He, Rong
    Liu, Yun
    Su, Xiaona
    Zhao, Lianhua
    Wang, Ge
    ONCOLOGY REPORTS, 2018, 39 (05) : 2270 - 2278
  • [8] The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition
    Yosaatmadja, Yuliana
    Patterson, Adam Vorn
    Smaill, Jeff Bruce
    Squire, Christopher John
    ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2015, 71 : 525 - 533
  • [9] AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer
    Aytatli, Abdulmelik
    Barlak, Neslisah
    Sanli, Fatma
    Caglar, Hasan Onur
    Gundogdu, Betul
    Tatar, Arzu
    Ittmann, Michael
    Karatas, Omer Faruk
    CELLULAR ONCOLOGY, 2022, 45 (01) : 41 - 56
  • [10] The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression
    Lee, Yoo-Young
    Ryu, Ji-Yoon
    Cho, Young-Jae
    Choi, Ju-Yeon
    Choi, Jung-Joo
    Choi, Chel Hun
    Sa, Jason K.
    Hwang, Jae Ryoung
    Lee, Jeong-Won
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
12345